Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 36,036 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 36,036 shares of Relay Therapeutics stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $4.63, for a total value of $166,846.68. Following the completion of the transaction, the chief financial officer now directly owns 263,190 shares of the company’s stock, valued at $1,218,569.70. This represents a 12.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, January 30th, Thomas Catinazzo sold 20,791 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.42, for a total value of $91,896.22.
• On Friday, December 27th, Thomas Catinazzo sold 4,865 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.42, for a total transaction of $21,503.30.

Relay Therapeutics Trading Up 1.3 %

Shares of NASDAQ:RLAY opened at $4.54 on Friday. Relay Therapeutics, Inc. has a 52-week low of $3.50 and a 52-week high of $11.16. The company has a fifty day moving average of $4.53 and a 200-day moving average of $6.12.

Relay Therapeutics (NASDAQ:RLAY) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.14. During the same period last year, the firm posted ($0.54) earnings per share. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. As a group, equities research analysts predict that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Relay Therapeutics in the 3rd quarter valued at approximately $63,000. Portland Investment Counsel Inc. bought a new stake in shares of Relay Therapeutics in the third quarter worth $71,000. Values First Advisors Inc. acquired a new stake in Relay Therapeutics in the third quarter valued at $75,000. Savant Capital LLC bought a new position in Relay Therapeutics during the 4th quarter worth $120,000. Finally, Point72 DIFC Ltd acquired a new position in Relay Therapeutics during the 3rd quarter worth about $134,000. Institutional investors own 96.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on RLAY shares. JMP Securities reissued a “market outperform” rating and issued a $21.00 target price on shares of Relay Therapeutics in a report on Thursday, December 12th. Leerink Partners lowered their price objective on shares of Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, December 4th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Relay Therapeutics in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.50.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.